General Federal Contracts — July 24, 2026

Leidos Holdings' subsidiary won a cost-plus-fixed-fee delivery order from the NIH National Cancer Institute for Phase 1/2 vaccine trials through 2029. With $36.8M already funded and cost-plus pricing minimizing profit volatility, this provides stable, long-term revenue visibility of ~$28.9M annually.

Frequentis USA received a $124.6M time-and-materials delivery order for APC units and APCMS, with $105.1M already outlayed (84% funded). The contract runs through 2027, and the high funding certainty suggests potential for follow-on orders or extensions as FAA modernizes telecom infrastructure.

Raytheon's sole-source, cost-plus-fixed-fee delivery order under the FAA's STARS program runs through June 2025, with no modifications or extensions noted. At ~$28.3M annual revenue, it is immaterial to RTX ($69B+ revenue), but its completion creates a gap in FAA-related revenue for the company's government services segment.

PTSI Managed Services' $130.8M NASA contract is substantially complete (78% paid) with no visible follow-on awards at Goddard Space Flight Center. This single contract likely represents a significant portion of PTSI's federal portfolio, creating revenue concentration risk.

All four contracts are civilian (HHS, NASA, FAA), making them vulnerable to discretionary budget cuts or Continuing Resolution delays, particularly the Leidos NIH contract which depends on annual appropriations for the $173.3M ceiling to be fully funded.

Frequentis USA's $124.6M FAA contract was awarded under full and open competition with no set-aside, meaning the company faces potential displacement by larger competitors (e.g., L3Harris, Collins Aerospace) at re-compete in 2027.

Leidos' NIH vaccine trial contract positions the company for expanded health R&D work. Successful Phase 1/2 outcomes could lead to larger Phase 3 contracts or follow-on awards for commercial-scale production, leveraging the cost-plus pricing model.

Raytheon's sole-source award under the FAA STARS program demonstrates an entrenched incumbent position. As the FAA modernizes en route and terminal air traffic control systems, Raytheon could secure additional sole-source task orders for ground handling equipment and related engineering services.

Two FAA contracts totaling $237.7M (Frequentis USA and Raytheon) highlight sustained investment in air traffic control and telecom infrastructure. The Leidos NIH contract adds $173.3M in health R&D, indicating civilian agencies are driving steady, non-defense government services spending.

Two of four contracts (Leidos at $173.3M and Raytheon at $113.2M) use cost-plus-fixed-fee pricing, which reduces profit volatility for contractors. This pricing model is prevalent in civilian R&D and engineering services, offering stable margins but limited upside.

{"entity" => "Leidos Holdings Inc. (LDOS)", "reason" => "Largest contract in the digest ($173.3M) with long duration through 2029; cost-plus pricing provides stable revenue but full funding depends on NIH appropriations.", "trigger" => "FY2027 NIH budget approval; vaccine trial Phase 2 completion announcements"}

{"entity" => "Frequentis USA, Inc.", "reason" => "High funding certainty ($105.1M outlayed of $124.6M) but faces re-compete risk in 2027; foreign ownership adds regulatory scrutiny.", "trigger" => "FAA telecom equipment re-compete RFP release; Committee on Foreign Investment in the United States (CFIUS) review updates"}

{"entity" => "PTSI Managed Services Inc.", "reason" => "Contract is substantially complete with no visible follow-on; single-contract concentration risk is high.", "trigger" => "NASA Goddard facility contract re-compete announcements; PTSI's federal contract portfolio disclosures"}